Your Health, We Care
In patients with chronic liver disease, the most common adverse reactions (≥ 3%) were pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.
In patients with chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.
from FDA，2021.06
Avatrombopag is an innovative drug that has shown significant results in the tre···【more】
Release date：2025-02-06Recommended：144
Avatrombopag is a novel thrombopoietin receptor agonist, and its safety and side···【more】
Release date：2025-02-06Recommended：131
Avatrombopag is a drug used to treat thrombocytopenia, but its side effects are ···【more】
Release date：2025-02-05Recommended：101
Avatrombopag is a drug used to treat thrombocytopenia, but its use may be accomp···【more】
Release date：2025-02-05Recommended：104
